Edgewise Therapeutics, Inc.

EWTX

Edgewise Therapeutics, Inc.

EWTX

Insider Sentiment (TTM):

Last Purchase:2025-11-11Last Sale:2026-05-05Shares Purchased (TTM):10,700Shares Sold (TTM):431,829

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:118,108,845Shares Outstanding:107,116,709Institutional Ownership Pct.:110.26%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	72	33	61	46	43	50	42	45	43	30	86	33
Marketable Securities	388	466	469	517	551	386	429	448	468	502	232	257
Prepaid Expense And Other Assets Current	6	10	13	11	9	7	5	7	8	9	9	8
Assets Current	472	510	543	574	603	443	475	499	519	541	327	298
Property Plant And Equipment Net	7	7	8	8	9	9	10	10	10	10	10	11
Operating Lease Right Of Use Asset	1	1	1	1	1	2	2	2	2	2	2	2
Other Assets Noncurrent	-	-	-	-	-	1	0	0	0	-	0	0
Assets	480	519	553	583	613	454	487	511	532	554	340	311
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	7	6	6	8	9	6	6	7	5	4	5
Employee Related Liabilities Current	9	6	12	8	6	4	10	6	4	3	6	4
Accrued Liabilities Current	5	9	8	6	6	7	7	6	5	6	6	6
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	29	23	27	22	21	21	24	19	17	15	17	16
Operating Lease Liability Noncurrent	3	3	3	3	3	4	4	3	4	4	4	5
Liabilities	32	25	30	25	24	25	28	22	21	19	21	21
Stockholders Equity Inclu…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,101	1,089	1,068	1,054	1,044	849	837	827	816	809	563	505
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	1	1	0	0	0	1	-1	-1	0	-0
Retained Earnings Accumulated Deficit	-653	-595	-546	-496	-455	-419	-379	-339	-305	-273	-245	-215
Stockholders Equity	448	493	522	559	589	430	459	489	510	535	319	290
Liabilities And Stockholders Equity	480	519	553	583	613	454	487	511	532	554	340	311
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000
Common Stock Shares Issued	108	107	106	106	105	95	95	94	94	93	70	63
Shares Outstanding	108	107	106	106	105	95	95	94	94	93	70	63

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.99%	16.53%	14.78%	-	-	-	-	-	-	-	-	-
2025	-2.86%	-10.41%	-3.95%	10.81%	23.94%	17.22%	52.37%	54.18%	67.41%	-2.02%	16.08%	11.56%
2024	-14.35%	-9.95%	-5.10%	15.81%	61.15%	116.06%	-6.86%	-18.88%	-20.12%	-8.85%	-41.87%	-44.34%
2023	-	-	-	-4.30%	-14.99%	-7.27%	8.22%	91.26%	188.81%	-2.59%	-5.76%	5.53%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	16.24	22.61	19.85	26.51	28.87	20.99	19.93	26.35	30.24	37.08	19.50	18.23
Quick Ratio	16.01	22.16	19.37	26.03	28.43	20.67	19.71	25.98	29.79	36.49	18.98	17.73
Working Capital	442.48M	487.25M	516.02M	552.25M	582.36M	422.06M	451.62M	480.48M	502.27M	526.83M	310.23M	281.58M
Leverage & Debt
Debt to Equity	0.07	0.05	0.06	0.04	0.04	0.06	0.06	0.05	0.04	0.04	0.07	0.07
Debt Ratio	0.07	0.05	0.05	0.04	0.04	0.05	0.06	0.04	0.04	0.03	0.06	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.83	-1.64	-1.63	-1.49	-1.44	-1.54	-1.45	-1.32	-1.24	-1.21	-1.57	-1.41
Free Cash Flow Per Share TTM	-1.43	-1.39	-1.40	-0.90	-0.84	-1.25	-1.19	-1.17	-1.12	-1.14	-1.53	-1.35
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	30.87%	20.48%	25.40%	26.51%	30.05%	38.01%	33.60%	38.98%	42.67%	39.61%	48.08%	46.80%
EPS Growth (1Y)	27.55%	7.00%	12.58%	12.50%	15.89%	27.04%	-7.88%	-5.99%	-3.30%	0.87%	24.54%	19.94%
Valuation Metrics
P/E TTM	-22.18	-19.17	-15.22	-10.88	-9.13	-14.33	-18.44	-20.14	-14.53	-15.09	-6.96	-4.07
P/B TTM	9.76	6.84	4.89	3.06	2.34	4.87	5.37	5.12	3.30	2.99	2.19	1.25
Market Cap	4.37B	3.37B	2.55B	1.71B	1.38B	2.09B	2.47B	2.50B	1.68B	1.60B	697.14M	363.62M
Enterprise Value	4.30B	3.34B	2.49B	1.67B	1.33B	2.04B	2.43B	2.46B	1.64B	1.57B	611.04M	330.67M
Calculated Values
Free Cash Flow TTM	-154.40M	-148.97M	-144.07M	-94.73M	-87.76M	-119.36M	-110.34M	-110.10M	-104.72M	-99.39M	-97.69M	-85.85M
Net Debt	-72.32M	-33.21M	-61.15M	-46.00M	-43.40M	-49.92M	-41.67M	-44.81M	-43.49M	-30.26M	-86.10M	-32.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-05Sale

Owner: Donovan, Joanne M.

Title: CMO

Shares: 50,000

Price/Share: $38.57

Value: $1,928,500.00

Shares Owned: 4,367

Relationship: Officer

Ownership: Direct

2026-04-01Sale

Owner: Donovan, Joanne M.

Title: CMO

Shares: 28,662

Price/Share: $32.31

Value: $926,069.22

Shares Owned: 9,597

Relationship: Officer

Ownership: Direct

2026-03-31Sale

Owner: Donovan, Joanne M.

Title: CMO

Shares: 21,338

Price/Share: $32.12

Value: $685,376.56

Shares Owned: 9,597

Relationship: Officer

Ownership: Direct

2026-03-27Sale

Owner: Donovan, Joanne M.

Title: CMO

Shares: 16,358

Price/Share: $30.98

Value: $506,770.84

Shares Owned: 9,597

Relationship: Officer

Ownership: Direct

2026-01-21Sale

Owner: Edris, Badreddin

Title: -

Shares: 115,471

Price/Share: $29.44

Value: $3,399,466.24

Shares Owned: 19,820

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-05	Donovan, Joanne M.	Officer	CMO	Direct	Sale	50,000	38.57	$1,928,500.00	4,367	4
2026-04-01	Donovan, Joanne M.	Officer	CMO	Direct	Sale	28,662	32.31	$926,069.22	9,597	4
2026-03-31	Donovan, Joanne M.	Officer	CMO	Direct	Sale	21,338	32.12	$685,376.56	9,597	4
2026-03-27	Donovan, Joanne M.	Officer	CMO	Direct	Sale	16,358	30.98	$506,770.84	9,597	4
2026-01-21	Edris, Badreddin	Director	-	Direct	Sale	115,471	29.44	$3,399,466.24	19,820	4
2025-11-12	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	100,000	21.12	$2,112,000.00	23,400	4
2025-11-11	Fox, Jonathan C	Director	-	Direct	Purchase	10,700	18.64	$199,448.00	23,702	4
2025-08-26	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	100,000	14.60	$1,460,000.00	23,400	4
2025-08-12	Donovan, Joanne M.	Officer	CMO	Direct	Sale	2,862	13.39	$38,322.18	25,361	4
2025-08-12	Moore, John R	Officer	General Counsel	Direct	Sale	2,098	13.39	$28,092.22	10,214	4
2025-08-12	Carruthers, R Michael	Officer	Chief Financial Officer	Direct	Sale	1,428	13.39	$19,120.92	86,162	4
2025-08-12	Koch, Kevin	Director,Officer	President and CEO	Direct	Sale	7,972	13.39	$106,745.08	30,615	4
2025-08-12	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	1,907	13.39	$25,534.73	23,400	4
2025-08-12	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	2,491	13.39	$33,354.49	23,645	4
2025-05-02	Donovan, Joanne M.	Officer	CMO	Direct	Sale	5,187	16.45	$85,326.15	21,588	4
2025-05-02	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	1,551	16.45	$25,513.95	18,521	4
2025-05-02	Carruthers, R Michael	Officer	Chief Financial Officer	Direct	Sale	1,314	16.45	$21,615.30	81,014	4
2025-05-02	Koch, Kevin	Director,Officer	President and CEO	Direct	Sale	4,276	16.45	$70,340.20	20,619	4
2025-05-02	Moore, John R	Officer	General Counsel	Direct	Sale	1,930	16.45	$31,748.50	6,531	4
2025-05-02	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	1,691	16.45	$27,816.95	20,355	4
2025-04-03	Orbimed, Genesis Gp Llc, …	Director,TenPercentOwner	-	Indirect	Purchase	496,771	20.13	$10,000,000.23	14,809,075	4
2025-04-03	Thompson, Peter A.	Director,TenPercentOwner	-	Indirect	Purchase	496,771	20.13	$10,000,000.23	14,809,075	4
2025-03-07	Koch, Kevin	Director,Officer	President and CEO	Direct	Sale	100	30.00	$3,000.00	14,478	4
2025-03-07	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	200	30.02	$6,004.00	14,863	4
2025-02-06	Koch, Kevin	Director,Officer	President and CEO	Direct	Sale	900	31.13	$28,017.00	14,478	4
2025-02-06	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	1,200	30.13	$36,156.00	14,863	4
2025-02-05	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	10,000	30.03	$300,300.00	16,837	4
2025-01-28	Donovan, Joanne M.	Officer	CMO	Direct	Sale	25,000	27.63	$690,750.00	16,358	4
2024-12-30	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	100,000	27.37	$2,737,000.00	14,863	4
2024-12-24	Semigran, Marc	Officer	Chief Development Officer	Direct	Sale	29,709	29.87	$887,407.83	6,716	4
2024-09-23	Moore, John R	Officer	General Counsel	Direct	Sale	20,922	27.63	$578,074.86	3,252	4
2024-09-20	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	42,068	29.03	$1,221,234.04	15,121	4
2024-09-20	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	75,000	28.88	$2,166,000.00	12,719	4
2024-09-20	Donovan, Joanne M.	Officer	CMO	Direct	Sale	7,162	28.29	$202,612.98	14,538	4
2024-09-20	Carruthers, R Michael	Officer	Chief Financial Officer	Direct	Sale	125,092	28.58	$3,575,129.36	6,904	4
2024-05-02	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	1,718	18.91	$32,487.38	13,422	4
2024-05-02	Carruthers, R Michael	Officer	Chief Financial Officer	Direct	Sale	2,157	18.91	$40,788.87	35,230	4
2024-05-02	Donovan, Joanne M.	Officer	CMO	Direct	Sale	3,682	18.91	$69,626.62	19,897	4
2024-05-02	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	1,576	18.91	$29,802.16	7,238	4
2024-05-02	Koch, Kevin	Director,Officer	President and CEO	Direct	Sale	3,152	18.91	$59,604.32	14,478	4
2024-05-02	Moore, John R	Officer	General Counsel	Direct	Sale	1,956	18.91	$36,987.96	3,252	4
2024-02-09	Moore, John R	Officer	General Counsel	Direct	Sale	8,029	20.01	$160,660.29	0	4
2024-02-09	Derakhshan, Behrad	Officer	Chief Business Officer	Direct	Sale	4,800	20.04	$96,192.00	7,020	4
2024-01-23	Thompson, Peter A.	Director,TenPercentOwner	-	Indirect	Purchase	454,545	11.00	$4,999,995.00	14,436,497	4
2024-01-23	Carruthers, R Michael	Officer	Chief Financial Officer	Direct	Sale	90,000	15.78	$1,420,200.00	29,024	4
2024-01-23	Orbimed, Capital Gp Vi Ll…	Director,TenPercentOwner	-	Indirect	Purchase	454,545	11.00	$4,999,995.00	14,436,497	4
2023-12-27	Moore, John R	Officer	General Counsel	Direct	Sale	8,497	10.50	$89,218.50	0	4
2023-12-26	Russell, Alan J	Director,Officer	Chief Scientific Officer	Direct	Sale	172,585	9.33	$1,610,218.05	3,606	4
2023-12-26	Fox, Jonathan C	Director	-	Direct	Purchase	10,857	9.30	$100,970.10	10,857	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

110.26%

Inst. Shares: 118,108,845

Shares Outstanding: 107,116,709

2025-12-31

118.08%

Inst. Shares: 121,537,708

Shares Outstanding: 102,930,744

2025-09-30

104.78%

Inst. Shares: 110,530,464

Shares Outstanding: 105,492,779

2025-06-30

112.48%

Inst. Shares: 118,041,189

Shares Outstanding: 104,940,493

2025-03-31

109.99%

Inst. Shares: 104,631,874

Shares Outstanding: 95,130,053

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	118,108,845	107,116,709	110.26%
2025-12-31	121,537,708	102,930,744	118.08%
2025-09-30	110,530,464	105,492,779	104.78%
2025-06-30	118,041,189	104,940,493	112.48%
2025-03-31	104,631,874	95,130,053	109.99%
2024-12-31	98,374,642	92,414,626	106.45%
2024-09-30	100,760,246	93,813,346	107.41%
2024-06-30	101,092,566	93,515,356	108.10%
2024-03-31	91,217,431	87,567,307	104.17%
2023-12-31	78,372,955	63,723,600	122.99%
2023-09-30	67,927,607	63,459,560	107.04%
2023-06-30	68,977,124	63,380,430	108.83%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Edgewise Therapeutics, Inc. (EWTX) — SEC Financial Statements & Analysis

Edgewise Therapeutics, Inc. (EWTX) is a pharmaceutical preparations company, incorporated in DE. Edgewise Therapeutics, Inc. trades on Nasdaq as: EWTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Edgewise Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 9.76x (TTM), at a market cap of $4.37B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.07x
P/B TTM: 9.76x
Market Cap: $4.37B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Edgewise Therapeutics, Inc. in?

Edgewise Therapeutics, Inc. (EWTX) operates in the Pharmaceutical Preparations industry.

What is EWTX's market cap?

Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $4.37B as of 2026-06-30.

What exchange does EWTX trade on?

Edgewise Therapeutics, Inc. (EWTX) trades on the Nasdaq.

Where is Edgewise Therapeutics, Inc. incorporated?

Edgewise Therapeutics, Inc. is incorporated in DE.